<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02787785</url>
  </required_header>
  <id_info>
    <org_study_id>MADIT S-ICD (C1834)</org_study_id>
    <nct_id>NCT02787785</nct_id>
  </id_info>
  <brief_title>Multicenter Automatic Defibrillator Implantation Trial With Subcutaneous Implantable Cardioverter Defibrillator</brief_title>
  <acronym>MADIT S-ICD</acronym>
  <official_title>Multicenter Automatic Defibrillator Implantation Trial With Subcutaneous Implantable Cardioverter Defibrillator (MADIT S-ICD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The MADIT S-ICD trial is designed to evaluate if subjects with a prior myocardial infarction,&#xD;
      diabetes mellitus and a relatively preserved ejection fraction of 36-50% will have a survival&#xD;
      benefit from receiving a subcutaneous implantable cardioverter defibrillator (S-ICD) when&#xD;
      compared to those receiving conventional medical therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, subjects will be randomized to receive a subcutaneous implantable cardioverter&#xD;
      defibrillator or Conventional Medical Therapy (CMT). Randomization will be stratified by&#xD;
      enrolling site, in a 2:1 (S-ICD:CMT) scheme. Length of follow-up for each subject will be&#xD;
      dependent on the date of entry into the study, since all subjects will be followed to a&#xD;
      common study termination date.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 17, 2017</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All-Cause Mortality</measure>
    <time_frame>Through study completion,estimated average of 2.6 years follow-up</time_frame>
    <description>This study is event driven so there is no set end date for follow-up or analysis. Subjects will be followed until the statistical boundary is crossed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-Cause Mortality in various subgroups</measure>
    <time_frame>Through study completion,estimated average of 2.6 years follow-up</time_frame>
    <description>This study is event driven so there is no set end date for follow-up or analysis. Subjects will be followed until the statistical boundary is crossed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sudden Death in various subgroups</measure>
    <time_frame>Through study completion,estimated average of 2.6 years follow-up</time_frame>
    <description>This study is event driven so there is no set end date for follow-up or analysis. Subjects will be followed until the statistical boundary is crossed.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>S-ICD Inappropriate shock frequency</measure>
    <time_frame>Through study completion,estimated average of 2.6 years follow-up</time_frame>
    <description>Pre-specific tertiary statistical analyses will be descriptive and exploratory</description>
  </other_outcome>
  <other_outcome>
    <measure>S-ICD Inappropriate shock outcomes</measure>
    <time_frame>Through study completion,estimated average of 2.6 years follow-up</time_frame>
    <description>Pre-specific tertiary statistical analyses will be descriptive and exploratory</description>
  </other_outcome>
  <other_outcome>
    <measure>S-ICD treated ventricular arrhythmia frequency</measure>
    <time_frame>Through study completion,estimated average of 2.6 years follow-up</time_frame>
    <description>Pre-specific tertiary statistical analyses will be descriptive and exploratory</description>
  </other_outcome>
  <other_outcome>
    <measure>S-ICD treated ventricular arrhythmia outcomes</measure>
    <time_frame>Through study completion,estimated average of 2.6 years follow-up</time_frame>
    <description>Pre-specific tertiary statistical analyses will be descriptive and exploratory</description>
  </other_outcome>
  <other_outcome>
    <measure>S-ICD device complications</measure>
    <time_frame>Through study completion, estimated average of 2.6 years follow-up</time_frame>
    <description>Pre-specific tertiary statistical analyses will be descriptive and exploratory</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Tachycardia</condition>
  <condition>Diabetes Mellitus</condition>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>Conventional Medical Therapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>This arm of the trial continues with their current conventional medical therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subcutaneous Implantable Cardioverter Defibrillator</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This arm of the trial receives a subcutaneous implantable defibrillator.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Subcutaneous Implantable Cardioverter Defibrillator</intervention_name>
    <description>The S-ICD is an entirely subcutaneous implantable cardioverter defibrillator.</description>
    <arm_group_label>Subcutaneous Implantable Cardioverter Defibrillator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age â‰¥ 65 years on date of consent&#xD;
&#xD;
          -  Diabetes mellitus treated with oral hypoglycemic agents, non-insulin injectable and/or&#xD;
             insulin for the past 3 calendar months or longer prior to consent date&#xD;
&#xD;
          -  LV ejection fraction (LVEF) of 36-50% documented by imaging (preferably by MRI or&#xD;
             echocardiographic methods), within 12 calendar months before consent date and at least&#xD;
             3 calendar months after most recent Myocardial Infarction (MI), percutaneous coronary&#xD;
             intervention (PCI) or coronary artery bypass graft (CABG).&#xD;
&#xD;
          -  One or more clinically documented, enzyme-positive myocardial infarctions, more than 3&#xD;
             calendar months prior to consent date*. (If enzyme information and clinical&#xD;
             documentation is not available, there must be a clear evidence of prior silent&#xD;
             myocardial infarction identified as either new pathologic Q waves on ECG or imaging&#xD;
             documentation of an infarcted area (left ventricular angiography/ nuclear scan/ MRI)&#xD;
             Note: MI qualification based on the Universal Definition of MI)&#xD;
&#xD;
          -  Qualifying 12-lead ECG within 6 calendar months before consent date and at least 3&#xD;
             calendar months after most recent MI, PCI or CABG. (The qualifying ECG* can be sinus&#xD;
             rhythm or atrial fibrillation (patients with persistent or permanent atrial&#xD;
             fibrillation should have a controlled ventricular response &lt;100 bpm on consent date)&#xD;
             *QRS duration on the qualifying ECG &gt;90 msec)&#xD;
&#xD;
          -  Passing S-ICD Screening ECG performed per applicable user's manual on or after the&#xD;
             consent date that identifies one or more qualifying S-ICD sensing vectors&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Ejection fraction &gt;50% or &lt;36% within 12 calendar months prior to consent date and at&#xD;
             least 3 calendar months after the most recent MI, PCI or CABG&#xD;
&#xD;
          -  Existing guideline based indication for an implantable cardioverter defibrillator&#xD;
             (ICD), pacemaker, cardiac resynchronization therapy device (CRT), or cardiac&#xD;
             resynchronization therapy device with defibrillator (CRT-D) therapy&#xD;
&#xD;
          -  Existing or previously implanted ICD, CRT, CRT-D, or pacemaker device system&#xD;
&#xD;
          -  Active infection at the time of consent&#xD;
&#xD;
          -  Contraindication for S-ICD implantation according to the S-ICD pulse generator (PG)&#xD;
             User's Manual&#xD;
&#xD;
          -  Hemodialysis and/or peritoneal dialysis at the time of enrollment&#xD;
&#xD;
          -  New York Heart Association Class IV in the past 3 calendar months prior to or at the&#xD;
             time of consent date&#xD;
&#xD;
          -  Coronary artery bypass graft surgery or percutaneous coronary intervention (balloon&#xD;
             and/or stent angioplasty) within 3 calendar months prior to the consent date&#xD;
&#xD;
          -  Enzyme-positive myocardial infarction or silent myocardial infarction diagnosed within&#xD;
             3 calendar months prior to the consent date&#xD;
&#xD;
          -  Unstable angina with need for outpatient treatment or hospitalization (change/addition&#xD;
             of anti-anginal medication and/or coronary revascularization), within 3 calendar&#xD;
             months prior to the consent date&#xD;
&#xD;
          -  Angiographic evidence of coronary disease in a patient that is a candidate for&#xD;
             coronary revascularization and is likely to undergo CABG or PCI in the next 3 calendar&#xD;
             months&#xD;
&#xD;
          -  High risk for arterial embolism (e.g. presence of mobile left ventricular thrombus)&#xD;
&#xD;
          -  Hemodynamically significant congenital heart disease, aortic valvular heart disease,&#xD;
             or amyloid heart disease&#xD;
&#xD;
          -  Baseline body mass index &gt; 45 kg/m2&#xD;
&#xD;
          -  On a heart transplant list or likely to undergo heart transplant within one calendar&#xD;
             year&#xD;
&#xD;
          -  Presence of any other disease, other than the subject's cardiac disease, that in the&#xD;
             opinion of the investigator is likely to significantly reduce the patient's likelihood&#xD;
             of survival for the duration of the trial (e.g. cancer, liver failure).&#xD;
&#xD;
          -  Unwillingness or inability to cooperate with the protocol&#xD;
&#xD;
          -  Resides at such a distance from the enrolling site so travel to follow-up visits would&#xD;
             be unusually difficult&#xD;
&#xD;
          -  Reversible causes of heart disease (e.g. viral myocarditis or tachycardia induced&#xD;
             cardiomyopathy)&#xD;
&#xD;
          -  Participation in other clinical trials (observational registries are allowed with&#xD;
             approval from the CDC)&#xD;
&#xD;
          -  Does not anticipate residing in the vicinity of the enrolling site for the duration of&#xD;
             the trial&#xD;
&#xD;
          -  Unwillingness to sign the consent for participation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Valentina Kutyifa, MD, MSc, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rochester Heart Research Follow-up Program</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Heart Center Research, LLC.</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic- Scottsdale</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Bernard's Medical Center</name>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <zip>72401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glendale Adventist Medical Center</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedar-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alta Bates Summit Hospital</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huntington Hospital</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tallahassee Research Institute</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>32308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Elizabeth Healthcare</name>
      <address>
        <city>Edgewood</city>
        <state>Kentucky</state>
        <zip>41017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Cardiovascular Specialists</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Luke's Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nebraska Heart Institute</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68526</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catholic Medical Center</name>
      <address>
        <city>Manchester</city>
        <state>New Hampshire</state>
        <zip>03102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Associates of Delaware Valley</name>
      <address>
        <city>Haddon Heights</city>
        <state>New Jersey</state>
        <zip>08035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwell Health</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Strong Memorial / University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Carolina Heart and Vascular</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio Health Research Institute</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Promedica Toledo Hospital</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abington Memorial Hospital</name>
      <address>
        <city>Abington</city>
        <state>Pennsylvania</state>
        <zip>19008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phoenixville Hospital</name>
      <address>
        <city>Phoenixville</city>
        <state>Pennsylvania</state>
        <zip>19460</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center - Presbyterian</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erlanger Medical Center</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas, Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sentara Norfolk General</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PeaceHealth Southwest Medical Center</name>
      <address>
        <city>Vancouver</city>
        <state>Washington</state>
        <zip>98664</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>HannÃ¶ver</city>
        <state>Niedersachsen</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unfallkrankenhaus Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>12683</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinik Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassah Hebrew University Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaplan Medical Center</name>
      <address>
        <city>Rechovot</city>
        <zip>76100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>6423906</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Ospedale Niguarda CA Granda</name>
      <address>
        <city>Milano</city>
        <state>Niguarda</state>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria</name>
      <address>
        <city>Verona</city>
        <zip>37126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMC Utrecht</name>
      <address>
        <city>Utrecht</city>
        <state>CX</state>
        <zip>3584</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Medisch Centrum</name>
      <address>
        <city>Amsterdam</city>
        <state>NH</state>
        <zip>1105AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Miguel Servet</name>
      <address>
        <city>Zaragosa</city>
        <state>Aragon</state>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Navarra, Department of Cardiology</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Zurich</name>
      <address>
        <city>ZÃ¼rich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 18, 2016</study_first_submitted>
  <study_first_submitted_qc>May 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 1, 2016</study_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Subcutaneous</keyword>
  <keyword>Implantable Cardioverter Defibrillator</keyword>
  <keyword>MADIT</keyword>
  <keyword>Diabetes</keyword>
  <keyword>Myocardial Infarction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Tachycardia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

